Efficacy of liraglutide added to sodium-glucose cotransporter-2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post-hoc analysis of LIRA-ADD2SGLT2i.

Blonde L, Fainberg U, Kaltoft MS, Mosenzon O, Ramesh C, Rea R

Diabetes, obesity & metabolism8 Jul 2021Cited by 4 (Europe PMC)

PMID34132018PMCIDPMC8518913DOI10.1111/dom.14464PepBankPUB-34132018

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on SGLT2 inhibitors, the HbA1c response to liraglutide differed by baseline HbA1c tertile (interaction P = .011).
In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, the HbA1c benefit of liraglutide was different at different starting HbA1c levels.
Peptide
Liraglutide
Outcome
MixedInteraction of baseline HbA1c with HbA1c response
Study
n = 303
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
There was a significant interaction between baseline HbA1c tertiles (7.0%-[interaction] = .011), with the lowest HbA1c estimated treatment difference (95% confidence interval) observed in patients with lowest baseline HbA1c…
2 context sentences(design, population, supporting numbers)
Summary · context
LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1).
Summary · context
Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed.
Report a problemFND-3413201804
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on SGLT2 inhibitors, baseline BMI did not significantly change the glycaemic response to liraglutide.
In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, the blood sugar benefit of liraglutide did not differ by starting body mass index.
Peptide
Liraglutide
Outcome
No significant changeInteraction of baseline BMI with glycaemic control
Study
n = 303
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
There were no significant interactions in glycaemic control across baseline BMI, diabetes duration, insulin resistance determined by HOMA-IR or SGLT2i use duration (p_{[interaction]} > .05, all).
2 context sentences(design, population, supporting numbers)
Summary · context
LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1).
Summary · context
Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed.
Report a problemFND-3413201805
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on SGLT2 inhibitors, diabetes duration did not significantly change the glycaemic response to liraglutide.
In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, the blood sugar benefit of liraglutide did not differ by how long people had diabetes.
Peptide
Liraglutide
Outcome
No significant changeInteraction of diabetes duration with glycaemic control
Study
n = 303
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
There were no significant interactions in glycaemic control across baseline BMI, diabetes duration, insulin resistance determined by HOMA-IR or SGLT2i use duration (p_{[interaction]} > .05, all).
2 context sentences(design, population, supporting numbers)
Summary · context
LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1).
Summary · context
Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed.
Report a problemFND-3413201806
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on SGLT2 inhibitors, insulin resistance by HOMA-IR did not significantly change the glycaemic response to liraglutide.
In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, the blood sugar benefit of liraglutide did not differ by insulin resistance.
Peptide
Liraglutide
Outcome
No significant changeInteraction of HOMA-IR with glycaemic control
Study
n = 303
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
There were no significant interactions in glycaemic control across baseline BMI, diabetes duration, insulin resistance determined by HOMA-IR or SGLT2i use duration (p_{[interaction]} > .05, all).
2 context sentences(design, population, supporting numbers)
Summary · context
LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1).
Summary · context
Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed.
Report a problemFND-3413201807
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on SGLT2 inhibitors, the duration of SGLT2 inhibitor use did not significantly change the glycaemic response to liraglutide.
In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, liraglutide blood sugar benefit did not differ by how long they had used an SGLT2 inhibitor.
Peptide
Liraglutide
Outcome
No significant changeInteraction of SGLT2i use duration with glycaemic control
Study
n = 303
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
There were no significant interactions in glycaemic control across baseline BMI, diabetes duration, insulin resistance determined by HOMA-IR or SGLT2i use duration (p_{[interaction]} > .05, all).
2 context sentences(design, population, supporting numbers)
Summary · context
LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1).
Summary · context
Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed.
Report a problemFND-3413201808
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on SGLT2 inhibitors, none of the five baseline characteristics significantly changed the body weight response to liraglutide.
In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, the body weight change with liraglutide did not differ by any of the five starting characteristics.
Peptide
Liraglutide
Outcome
No significant changeInteraction of baseline characteristics with body weight change
Study
n = 303
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Across the five characteristics assessed, no significant interactions were found for body weight or waist circumference changes from baseline (p_{[interaction]} > .05, all).
2 context sentences(design, population, supporting numbers)
Summary · context
LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1).
Summary · context
Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed.
Report a problemFND-3413201809
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on SGLT2 inhibitors, none of the five baseline characteristics significantly changed the waist circumference response to liraglutide.
In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, the waist change with liraglutide did not differ by any of the five starting characteristics.
Peptide
Liraglutide
Outcome
No significant changeInteraction of baseline characteristics with waist circumference change
Study
n = 303
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 1.8 mg/day · 26 weeksAs given in this study (human).
Source sentences
Summary
Across the five characteristics assessed, no significant interactions were found for body weight or waist circumference changes from baseline (p_{[interaction]} > .05, all).
2 context sentences(design, population, supporting numbers)
Summary · context
LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1).
Summary · context
Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed.
Report a problemFND-3413201810
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on SGLT2 inhibitors, the week 26 HbA1c treatment difference for liraglutide versus placebo was -0.20% in the lowest baseline HbA1c tertile, with a CI that includes zero.
In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, liraglutide and placebo did not clearly differ in HbA1c change at the lowest starting HbA1c.
Peptide
Liraglutide
Outcome
No significant changeHbA1c treatment difference, lowest baseline HbA1c tertile (7.0%-<7.6%)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
HbA1c estimated treatment difference
−0.2%
baseline HbA1c 7.0%-<7.6%
Source sentences
Summary
There was a significant interaction between baseline HbA1c tertiles (7.0%-[interaction] = .011), with the lowest HbA1c estimated treatment difference (95% confidence interval) observed in patients with lowest baseline HbA1c…
2 context sentences(design, population, supporting numbers)
Summary · context
LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1).
Summary · context
Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed.
Report a problemFND-3413201801
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on SGLT2 inhibitors, the week 26 HbA1c treatment difference for liraglutide versus placebo was -0.68% in the middle baseline HbA1c tertile.
In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, liraglutide lowered HbA1c more than placebo in people with middle starting HbA1c.
Peptide
Liraglutide
Outcome
DecreaseHbA1c treatment difference, middle baseline HbA1c tertile (7.6%-8.1%)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
HbA1c estimated treatment difference
−0.68%
baseline HbA1c 7.6%-8.1%
Source sentences
Summary
There was a significant interaction between baseline HbA1c tertiles (7.0%-[interaction] = .011), with the lowest HbA1c estimated treatment difference (95% confidence interval) observed in patients with lowest baseline HbA1c…
2 context sentences(design, population, supporting numbers)
Summary · context
LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1).
Summary · context
Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed.
Report a problemFND-3413201802
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on SGLT2 inhibitors, the week 26 HbA1c treatment difference for liraglutide versus placebo was -0.98% in the highest baseline HbA1c tertile.
In plain wordsIn adults with type 2 diabetes on SGLT2 inhibitors, liraglutide lowered HbA1c more than placebo in people with the highest starting HbA1c.
Peptide
Liraglutide
Outcome
DecreaseHbA1c treatment difference, highest baseline HbA1c tertile (>=8.2%-9.5%)
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1.8 mg/day · 26 weeksAs given in this study (human).
Measurements
HbA1c estimated treatment difference
−0.98%
baseline HbA1c >=8.2%-9.5%
Source sentences
Summary
There was a significant interaction between baseline HbA1c tertiles (7.0%-[interaction] = .011), with the lowest HbA1c estimated treatment difference (95% confidence interval) observed in patients with lowest baseline HbA1c…
2 context sentences(design, population, supporting numbers)
Summary · context
LIRA-ADD2SGLT2i (NCT02964247) was a placebo-controlled, double-blind, multinational trial, wherein participants received liraglutide (≤1.8 mg/day) or placebo (randomized 2:1).
Summary · context
Changes from baseline to week 26 in haemoglobin A1c (HbA1c), body weight and waist circumference stratified by HbA1c, body mass index (BMI), diabetes duration, duration of pre-trial SGLT2i use and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) were analysed.
Report a problemFND-3413201803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02964247

LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

Novo Nordisk A/Sn = 3033 Mar 2017 to 8 May 2018

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 17 Nov 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.